Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.
All entries for: Oncology
March 31, 2026
Bicara Therapeutics Inc.
Neutral Outlook
Boston, MA
1-50 employees
The implementation of the IRA is currently subject to ongoing litigation that challenges the constitutionality of the IRA’s Medicare drug price negotiation program. The full impact of the IRA on our business and the pharmaceutical and healthcare industry in general is not yet known.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
Centessa Pharmaceuticals plc
Negative Outlook
London, UK
201-500 employees
Although the effects of the IRA on our business and the healthcare industry in general is not yet known we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Oncology, Rare Diseases
Drug Type: Small Molecule
March 31, 2026
HCW Biologics Inc.
Negative Outlook
Miramar, FL
1-50 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.
Disease Area: Immune Diseases, Oncology
Drug Type: Biologic
March 31, 2026
Decoy Therapeutics Inc
Neutral Outlook
Houston, TX
1-50 employees
In August 2022, the Inflation Reduction Act of 2022 was signed into law and requires the federal government to negotiate prices for some high-cost drugs covered under Medicare, requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for drugs used by Medicare beneficiaries, and caps Medicare beneficiaries’ out-of-pocket spending under the Medicare Part D benefit. We will monitor this issue to determine the effects of this legislation on our business.
Disease Area: Immune Diseases, Oncology
Drug Type: Small Molecule
March 31, 2026
LeonaBio
Neutral Outlook
Bothell, WA
1-50 employees
In August 2022, the Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes.
Disease Area: Oncology
Drug Type: Small Molecule
March 31, 2026
Novartis/NJ
Layoffs
East Hanover, NJ
10,000+ employees
Novartis is laying off 114 employees at its East Hanover, New Jersey site, with terminations running from June 26 through Nov. 27, continuing a pattern of workforce reductions at the location over the past year.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
March 30, 2026
Atkis Oncology
Neutral Outlook
Boston, MA
1-50 employees
Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and current or evolving federal policies regarding healthcare reform measures will impact the ACA or our business.
Disease Area: Oncology
Drug Type: Biologic
March 30, 2026
Oncolytics Biotech Inc
Negative Outlook
San Diego, CA
51-200 employees
We may not be able to adequately price our product or obtain third-party reimbursement for the cost of our product, which would adversely affect our sales and profitability. The healthcare industry is subject to significant regulatory reforms and cost containment pressures that could materially affect our business. In the U.S., there has been increasing legislative and regulatory focus on controlling pharmaceutical pricing. At the federal level, Congress passed the Inflation Reduction Act of 2022 (the “IRA”), which includes provisions that authorize the Secretary of Health and Human Services to negotiate prices with pharmaceutical companies for certain high-expenditure, single-source drugs covered under Medicare Part B or Part D programs, and provisions that impose rebates under Medicare Part B or Part D to penalize price increases that outpace inflation.
Disease Area: Oncology
Drug Type: Biologic
March 30, 2026
Terns Pharmaceuticals, Inc.
Neutral Outlook
Foster City, CA
51-200 employees
Regulatory guidance under the IRA, the OBBBA, and other tax-related legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to changes to federal tax legislation.
Disease Area: Metabolic Diseases, Oncology
Drug Type: Small Molecule